Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Moderna, Inc. (MRNA)

145.55 -3.32 (-2.23%)
At close: September 4 at 4:00:01 PM EDT
145.00 -0.55 (-0.38%)
After hours: September 4 at 7:59:59 PM EDT
Trade Moderna on Coinbase
Chart Range Bar
Loading chart for MRNA

What's happening with MRNA?

1h ago
Powered by Yahoo Scout

Moderna is advancing its pipeline with a Phase 3 trial for an mRNA bird flu vaccine, supported by significant funding and a commitment to equitable access. Despite recent stock volatility and valuation concerns, the company remains a key player in the mRNA space, particularly in oncology and infectious diseases.

Powered by Yahoo Scout
  • Previous Close 148.87
  • Open 153.00
  • Bid 138.81 x 100
  • Ask 149.00 x 700
  • Day's Range 141.52 - 154.04
  • 52 Week Range 22.28 - 176.66
  • Volume 14,924,137
  • Avg. Volume 15,751,570
  • Market Cap (intraday) 58.109B
  • Beta (5Y Monthly) 1.11
  • PE Ratio (TTM) --
  • EPS (TTM) -7.98
  • Earnings Date Nov 5, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 116.50

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

www.modernatx.com

4,700

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

MRNA
393.56%
S&P 500 (^GSPC)
12.75%

1-Year Return

MRNA
499.46%
S&P 500 (^GSPC)
18.71%

3-Year Return

MRNA
29.31%
S&P 500 (^GSPC)
70.93%

5-Year Return

MRNA
65.07%
S&P 500 (^GSPC)
70.18%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 143M
Earnings -782M
Profit Margin -546.85%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-1B
-500M
0
500M
1B
-500.0%
-400.0%
-300.0%
-200.0%
-100.0%

Analyst Insights

View More

Analyst Price Targets

45.00 Low
116.50 Average
145.55 Current
170.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 9/3/2026
Analyst Rothschild & Co
Rating Action Downgrade
Rating Sell
Price Action Raises
Price Target 40 -> 81

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (5yr expected)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -141.43%

  • Return on Assets (ttm)

    -13.26%

  • Return on Equity (ttm)

    -39.00%

  • Revenue (ttm)

    2.23B

  • Net Income Avi to Common (ttm)

    -3.15B

  • Diluted EPS (ttm)

    -7.98

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.14B

  • Total Debt/Equity (mrq)

    19.04%

  • Levered Free Cash Flow (ttm)

    299.25M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: